{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:57:07Z","timestamp":1792270627941,"version":"4.4.0"},"reference-count":30,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease, which often coexists with allergic rhinitis (AR). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13,\n key and central drivers of type 2 inflammation.  <jats:bold>Objective:<\/jats:bold> This <jats:italic>post hoc<\/jats:italic> analysis investigated the efficacy and safety of dupilumab in patients with severe CRSwNP with or without coexisting AR in the pooled phase III SINUS-24\/SINUS-52 studies.  <jats:bold>Methods:<\/jats:bold>\n Patients randomized to subcutaneous dupilumab 300 mg (n = 438) or placebo (n = 286) every 2 weeks for 24 (SINUS-24) or 52 weeks (SINUS-52) were analyzed. Pooled data from the first 24 weeks of treatment are presented. Changes from baseline in disease outcome measures and biomarker levels\n were analyzed by the patient-reported history of AR status.  <jats:bold>Results:<\/jats:bold> Overall, 338 of 724 patients (46.7%) had AR. Baseline characteristics were generally similar between patients with and those without AR. Dupilumab significantly improved objective and patient-reported\n measures of CRSwNP, including loss of smell, and reduced systemic and nasal biomarker levels versus placebo at week 24, with no significant treatment difference between patients with and those without AR. Use of systemic corticosteroids and\/or sinonasal surgery during treatment was significantly\n reduced with dupilumab versus placebo, irrespective of AR status (p \u2264 0.0029). The safety profile of dupilumab was similar in patients with and in patients without AR.  <jats:bold>Conclusion:<\/jats:bold> Dupilumab demonstrated significant improvements in both clinical end points and symptom\n scores versus placebo in patients with severe CRSwNP, irrespective of comorbid AR status, a common subgroup of patients often associated with poorer CRSwNP outcomes. Clinical trials NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52), &lt;ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\"\n xlink:href=\"http:\/\/www. IngetaConnect.com\"&gt;www.clinicaltrials.gov&lt;\/ext-link&gt;.<\/jats:p>","DOI":"10.2500\/aap.2023.44.230015","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T04:33:48Z","timestamp":1690000428000},"page":"265-274","source":"Crossref","is-referenced-by-count":29,"title":["Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis"],"prefix":"10.2500","volume":"44","author":[{"given":"Anju T.","family":"Peters","sequence":"first","affiliation":[{"name":"From the Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, D\u00fcsseldorf University Hospital, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif H.","family":"Khan","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nash","sequence":"additional","affiliation":[{"name":"Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, New York, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, New York, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[{"name":"Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, New York, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-020-00218-1","article-title":"Adult chronic rhinosinusitis","volume":"6","author":"Bachert","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cea.12472","article-title":"Pathogenesis of nasal polyposis","volume":"45","author":"Hulse","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/alr.22064","article-title":"Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population","volume":"8","author":"John Staniorski","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"B6","first-page":"343","article-title":"The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"B7","first-page":"PA5066","article-title":"Comorbidities, hypersensitivity and biomarkers in a real-world US nasal polyps population","volume":"54","author":"Scott","year":"2019","journal-title":"Eur Respir J"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lary.24418","article-title":"Analysis of comorbidities and objective parameters in refractory chronic rhinosinusitis","volume":"123","author":"Batra","year":"2013","journal-title":"Laryngoscope"},{"key":"B10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2500\/105065899781367500","article-title":"Correlation of allergy and severity of sinus disease","volume":"13","author":"Ramadan","year":"1999","journal-title":"Am J Rhinol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"key":"B12","doi-asserted-by":"crossref","first-page":"105947","DOI":"10.1016\/j.rmed.2020.105947","article-title":"Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry","volume":"166","author":"Canonica","year":"2020","journal-title":"Respir Med"},{"key":"B13","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B14","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/cea.12780","article-title":"Pathogenesis of rhinitis","volume":"46","author":"Eifan","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jaci.2012.05.052","article-title":"Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-\u03b3 and IL-4","volume":"130","author":"Soyka","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11882-010-0096-0","article-title":"Rhinosinusitis and asthma: a link for asthma severity","volume":"10","author":"Bachert","year":"2010","journal-title":"Curr Allergy Asthma Rep"},{"key":"B23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5415\/apallergy.2011.1.3.157","article-title":"Overview on the pathomechanisms of allergic rhinitis","volume":"1","author":"Pawankar","year":"2011","journal-title":"Asia Pac Allergy"},{"key":"B24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2020.05.026","article-title":"Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis","volume":"125","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/all.14338","article-title":"Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis","volume":"75","author":"Nettis","year":"2020","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40733-017-0036-z","article-title":"Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon","volume":"3","author":"Tan","year":"2017","journal-title":"Asthma Res Pract"},{"key":"B29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00408-023-00603-z","article-title":"Prevalence and severity distribution of type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis","volume":"201","author":"Khan","year":"2023","journal-title":"Lung"},{"key":"B30","article-title":"Medical dictionary for regulatory activities MedDRA term selection: points to consider"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2023\/00000044\/00000004\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T04:35:59Z","timestamp":1690346159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2023.44.230015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7,1]]}},"alternative-id":["1088-5412(20230701)44:4L.265;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2023.44.230015","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}